Current and future approach to the pathologist's assessment for targeted therapy in breast cancer

References

• Greene F L. American Joint Committee on Cancer. AJCC Cancer Staging Manual.6th ed. Springer-Verlag, New York 2002; xiv: 421
   Google Scholar
• Bloom H J, Richardson W W. Histological grading and prognosis in breast cancer; a study of 1409 cases of which 359 have been followed for 15 years. Br J Cancer 1957; 11: 359–377
   PubMed Web of Science ®Google Scholar
• Blamey R. The design and clinical use of the Nottingham Prognostic Index in breast cancer. Breast 1996; 5: 156–157
   Google Scholar
• Hanahan D, Weinberg R A. The hallmarks of cancer. Cell 2000; 100: 57–70
   PubMed Web of Science ®Google Scholar
• CenterWatch. Drugs Approved by the FDA. Center Watch, Boston 2008, http://www.centerwatch.com/patient/drugs/druglist. html (accessed 19 June 2008)
   Google Scholar
• Oldenhuis C N, Oosting S F, Gietema J A, de Vries E G. Prognostic versus predictive value of biomarkers in oncology. Eur J Cancer 2008; 44: 946–953
   PubMed Web of Science ®Google Scholar
• Gonzalez-Angulo A M, Morales-Vasquez F, Hortobagyi G N. Overview of resistance to systemic therapy in patients with breast cancer. Adv Exp Med Biol 2007; 608: 1–22
   PubMed Web of Science ®Google Scholar
• Petrelli A, Giordano S. From single- to multi-target drugs in cancer therapy: when aspecificity becomes an advantage. Curr Med Chem 2008; 15: 422–432
   PubMed Web of Science ®Google Scholar
• Schlotter C M, Vogt U, Allgayer H, Brandt B. Molecular targeted therapies for breast cancer treatment. Breast Cancer Res 2008; 10: 211
   PubMed Web of Science ®Google Scholar
• Beatson G. On the treatment of inoperable cases of carcinoma of the mamma: suggestion for a new method of treatment, with illustrative cases. Lancet 1896; 2: 104–107
   Google Scholar
• Jensen E, DeSombre E, Jungblut P. Estrogen Receptors in Hormone Responsive Tissues and Tumours. University of Chicago Press, Chicago 1969
   Google Scholar
• Nadji M, Gomez-Fernandez C, Ganjei-Azar P, Morales A R. Immunohistochemistry of estrogen and progesterone receptors reconsidered: experience with 5,993 breast cancers. Am J Clin Pathol 2005; 123: 21–27
   PubMed Web of Science ®Google Scholar
• Cheung K L. Endocrine therapy for breast cancer: an overview. Breast 2007; 16: 327–343
   PubMed Web of Science ®Google Scholar
• Early Breast Cancer Trialists' Collaborative Group (EBCTCG). Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials. Lancet 2005; 365: 1687–1717
   PubMed Web of Science ®Google Scholar
• Forbes J F, Cuzick J, Buzdar A, Howell A, Tobias J S, Baum M. Effect of anastrozole and tamoxifen as adjuvant treatment for early-stage breast cancer: 100-month analysis of the ATAC trial. Lancet Oncol 2008; 9: 45–53
   PubMed Web of Science ®Google Scholar
• Lin N U, Winer E P. Advances in adjuvant endocrine therapy for postmenopausal women. J Clin Oncol 2008; 26: 798–805
   PubMed Web of Science ®Google Scholar
• Harvey J M, Clark G M, Osborne C K, Allred D C. Estrogen receptor status by immunohistochemistry is superior to the ligand-binding assay for predicting response to adjuvant endocrine therapy in breast cancer. J Clin Oncol 1999; 17: 1474–1481
   PubMed Web of Science ®Google Scholar
• Rhodes A, Jasani B, Balaton A J, Miller K D. Immunohistochemical demonstration of oestrogen and progesterone receptors: correlation of standards achieved on in house tumours with that achieved on external quality assessment material in over 150 laboratories from 26 countries. J Clin Pathol 2000; 53: 292–301
   PubMed Web of Science ®Google Scholar
• Goldhirsch A, Glick J H, Gelber R D, Coates A S, Thurlimann B, Senn H J. Meeting highlights: international expert consensus on the primary therapy of early breast cancer 2005. Ann Oncol 2005; 16: 1569–1583
   PubMed Web of Science ®Google Scholar
• Slamon D J, Clark G M, Wong S G, Levin W J, Ullrich A, McGuire W L. Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science 1987; 235: 177–182
   PubMed Web of Science ®Google Scholar
• Slamon D J, Godolphin W, Jones L A, et al. Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer. Science 1989; 244: 707–712
   PubMed Web of Science ®Google Scholar
• Carter P, Presta L, Gorman C M, et al. Humanization of an anti-p185HER2 antibody for human cancer therapy. Proc Natl Acad Sci USA 1992; 89: 4285–4289
   PubMed Web of Science ®Google Scholar
• Baselga J, Perez E A, Pienkowski T, Bell R. Adjuvant trastuzumab: a milestone in the treatment of HER-2-positive early breast cancer. Oncologist 2006; 11(Suppl 1)4–12
   PubMed Web of Science ®Google Scholar
• Emens L A. Trastuzumab: targeted therapy for the management of HER-2/neu-overexpressing metastatic breast cancer. Am J Ther 2005; 12: 243–253
   PubMedGoogle Scholar
• Harries M, Smith I. The development and clinical use of trastuzumab (Herceptin). Endocr Relat Cancer 2002; 9: 75–85
   PubMed Web of Science ®Google Scholar
• Slamon D J, Leyland-Jones B, Shak S, et al. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med 2001; 344: 783–792
   PubMed Web of Science ®Google Scholar
• Marty M, Cognetti F, Maraninchi D, et al. Randomized phase II trial of the efficacy and safety of trastuzumab combined with docetaxel in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer administered as first-line treatment: the M77001 study group. J Clin Oncol 2005; 23: 4265–4274
   PubMed Web of Science ®Google Scholar
• Romond E H, Perez E A, Bryant J, et al. Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer. N Engl J Med 2005; 353: 1673–1684
   PubMed Web of Science ®Google Scholar
• Piccart-Gebhart M J, Procter M, Leyland-Jones B, et al. Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer. N Engl J Med 2005; 353: 1659–1672
   PubMed Web of Science ®Google Scholar
• Zhao J, Wu R, Au A, Marquez A, Yu Y, Shi Z. Determination of HER2 gene amplification by chromogenic in situ hybridization (CISH) in archival breast carcinoma. Mod Pathol 2002; 15: 657–665
   PubMed Web of Science ®Google Scholar
• van de Vijver M, Bilous M, Hanna W, et al. Chromogenic in situ hybridisation for the assessment of HER2 status in breast cancer: an international validation ring study. Breast Cancer Res 2007; 9: R68
   PubMed Web of Science ®Google Scholar
• Pothos A, Plastira K, Plastiras A, Vlachodimitropoulos D, Goutas N, Angelopoulou R. Comparison of chromogenic in situ hybridisation with fluorescence in situ hybridisation and immunohistochemistry for the assessment of her-2/neu oncogene in archival material of breast carcinoma. Acta Histochem Cytochem 2008; 41: 59–64
   PubMed Web of Science ®Google Scholar
• Bilous M, Morey A, Armes J, Cummings M, Francis G. Chromogenic in situ hybridisation testing for HER2 gene amplification in breast cancer produces highly reproducible results concordant with fluorescence in situ hybridisation and immunohistochemistry. Pathology 2006; 38: 120–124
   PubMed Web of Science ®Google Scholar
• Goldhirsch A, Wood W C, Gelber R D, Coates A S, Thurlimann B, Senn H J. Progress and promise: highlights of the international expert consensus on the primary therapy of early breast cancer 2007. Ann Oncol 2007; 18: 1133–1144
   PubMed Web of Science ®Google Scholar
• McShane L M, Altman D G, Sauerbrei W, Taube S E, Gion M, Clark G M. Reporting recommendations for tumor marker prognostic studies (REMARK). J Natl Cancer Inst 2005; 97: 1180–1184
   PubMed Web of Science ®Google Scholar
• Hayes D F, Bast R C, Desch C E, et al. Tumor marker utility grading system: a framework to evaluate clinical utility of tumor markers. J Natl Cancer Inst 1996; 88: 1456–1466
   PubMed Web of Science ®Google Scholar
• Williams C, Brunskill S, Altman D, et al. Cost-effectiveness of using prognostic information to select women with breast cancer for adjuvant systemic therapy. Health Technol Assess 2006; 10: iii-iv–ix-xi, 1-204
   Web of Science ®Google Scholar
• Lemmon M A. The EGF receptor family as therapeutic targets in breast cancer. Breast Dis 2003; 18: 33–43
   PubMedGoogle Scholar
• Klijn J G, Berns P M, Schmitz P I, Foekens J A. The clinical significance of epidermal growth factor receptor (EGF-R) in human breast cancer: a review on 5232 patients. Endocr Rev 1992; 13: 3–17
   PubMed Web of Science ®Google Scholar
• Modi S, D'Andrea G, Norton L, et al. A phase I study of cetuximab/paclitaxel in patients with advanced-stage breast cancer. Clin Breast Cancer 2006; 7: 270–277
   PubMed Web of Science ®Google Scholar
• Arpino G, Gutierrez C, Weiss H, et al. Treatment of human epidermal growth factor receptor 2-overexpressing breast cancer xenografts with multiagent HER-targeted therapy. J Natl Cancer Inst 2007; 99: 694–705
   PubMed Web of Science ®Google Scholar
• Reid A, Vidal L, Shaw H, de Bono J. Dual inhibition of ErbB1 (EGFR/HER1) and ErbB2 (HER2/neu). Eur J Cancer 2007; 43: 481–489
   PubMed Web of Science ®Google Scholar
• Geyer C E, Forster J, Lindquist D, et al. Lapatinib plus capecitabine for HER2-positive advanced breast cancer. N Engl J Med 2006; 355: 2733–2743
   PubMed Web of Science ®Google Scholar
• Kim K J, Li B, Winer J, et al. Inhibition of vascular endothelial growth factor-induced angiogenesis suppresses tumour growth in vivo. Nature 1993; 362: 841–844
   PubMed Web of Science ®Google Scholar
• Zhu Z, Bohlen P, Witte L. Clinical development of angiogenesis inhibitors to vascular endothelial growth factor and its receptors as cancer therapeutics. Curr Cancer Drug Targets 2002; 2: 135–156
   PubMed Web of Science ®Google Scholar
• Miller K D. E2100: a phase III trial of paclitaxel versus paclitaxel/bevacizumab for metastatic breast cancer. Clin Breast Cancer 2003; 3: 421–422
   PubMedGoogle Scholar
• Miller K D, Chap L I, Holmes F A, et al. Randomized phase III trial of capecitabine compared with bevacizumab plus capecitabine in patients with previously treated metastatic breast cancer. J Clin Oncol 2005; 23: 792–799
   PubMed Web of Science ®Google Scholar
• Al-Hajj M, Wicha M S, Benito-Hernandez A, Morrison S J, Clarke M F. Prospective identification of tumorigenic breast cancer cells. Proc Natl Acad Sci USA 2003; 100: 3983–3988
   PubMed Web of Science ®Google Scholar
• Costello R T, Mallet F, Gaugler B, et al. Human acute myeloid leukemia CD34+/CD38- progenitor cells have decreased sensitivity to chemotherapy and Fas-induced apoptosis, reduced immunogenicity, and impaired dendritic cell transformation capacities. Cancer Res 2000; 60: 4403–4411
   PubMed Web of Science ®Google Scholar
• Li X, Lewis M T, Huang J, et al. Intrinsic resistance of tumorigenic breast cancer cells to chemotherapy. J Natl Cancer Inst 2008; 100: 672–679
   PubMed Web of Science ®Google Scholar
• Farnie G, Clarke R B, Spence K, et al. Novel cell culture technique for primary ductal carcinoma in situ: role of Notch and epidermal growth factor receptor signaling pathways. J Natl Cancer Inst 2007; 99: 616–627
   PubMed Web of Science ®Google Scholar
• Cariati M, Naderi A, Brown J P, et al. Alpha-6 integrin is necessary for the tumourigenicity of a stem cell-like subpopulation within the MCF7 breast cancer cell line. Int J Cancer 2008; 122: 298–304
   PubMed Web of Science ®Google Scholar
• Reis-Filho J S, Simpson P T, Gale T, Lakhani S R. The molecular genetics of breast cancer: the contribution of comparative genomic hybridization. Pathol Res Pract 2005; 201: 713–725
   PubMed Web of Science ®Google Scholar
• van Beers E H, Nederlof P M. Array-CGH and breast cancer. Breast Cancer Res 2006; 8: 210
   PubMed Web of Science ®Google Scholar
• Callagy G, Pharoah P, Chin S F, et al. Identification and validation of prognostic markers in breast cancer with the complementary use of array-CGH and tissue microarrays. J Pathol 2005; 205: 388–396
   PubMed Web of Science ®Google Scholar
• Jonsson G, Naylor T L, Vallon-Christersson J, et al. Distinct genomic profiles in hereditary breast tumors identified by array-based comparative genomic hybridization. Cancer Res 2005; 65: 7612–7621
   PubMed Web of Science ®Google Scholar
• Wessels L F, van Welsem T, Hart A A, van't Veer L J, Reinders M J, Nederlof P M. Molecular classification of breast carcinomas by comparative genomic hybridization: a specific somatic genetic profile for BRCA1 tumors. Cancer Res 2002; 62: 7110–7117
   PubMed Web of Science ®Google Scholar
• Vincent-Salomon A, Gruel N, Lucchesi C, et al. Identification of typical medullary breast carcinoma as a genomic sub-group of basal-like carcinomas, a heterogeneous new molecular entity. Breast Cancer Res 2007; 9: R24
   PubMed Web of Science ®Google Scholar
• Simpson P T, Reis-Filho J S, Gale T, Lakhani S R. Molecular evolution of breast cancer. J Pathol 2005; 205: 248–254
   PubMed Web of Science ®Google Scholar
• Perou C M, Sorlie T, Eisen M B, et al. Molecular portraits of human breast tumours. Nature 2000; 406: 747–752
   PubMed Web of Science ®Google Scholar
• Sorlie T, Perou C M, Tibshirani R, et al. Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications. Proc Natl Acad Sci USA 2001; 98: 10869–10874
   PubMed Web of Science ®Google Scholar
• Sorlie T, Tibshirani R, Parker J, et al. Repeated observation of breast tumor subtypes in independent gene expression data sets. Proc Natl Acad Sci USA 2003; 100: 8418–8423
   PubMed Web of Science ®Google Scholar
• Morris S R, Carey L A. Molecular profiling in breast cancer. Rev Endocr Metab Disord 2007; 8: 185–198
   PubMed Web of Science ®Google Scholar
• Rakha E A, El-Sayed M E, Reis-Filho J S, Ellis I O. Expression profiling technology: its contribution to our understanding of breast cancer. Histopathology 2008; 52: 67–81
   PubMed Web of Science ®Google Scholar
• Sims A H, Ong K R, Clarke R B, Howell A. High-throughput genomic technology in research and clinical management of breast cancer. Exploiting the potential of gene expression profiling: is it ready for the clinic?. Breast Cancer Res 2006; 8: 214
   PubMed Web of Science ®Google Scholar
• van't Veer L J, Dai H, van de Vijver M J, et al. Gene expression profiling predicts clinical outcome of breast cancer. Nature 2002; 415: 530–536
   PubMed Web of Science ®Google Scholar
• Buyse M, Loi S, van't Veer L, et al. Validation and clinical utility of a 70-gene prognostic signature for women with node-negative breast cancer. J Natl Cancer Inst 2006; 98: 1183–1192
   PubMed Web of Science ®Google Scholar
• Paik S, Shak S, Tang G, et al. A multigene assay to predict recurrence of tamoxifen-treated, node-negative breast cancer. N Engl J Med 2004; 351: 2817–2826
   PubMed Web of Science ®Google Scholar
• Paik S, Tang G, Shak S, et al. Gene expression and benefit of chemotherapy in women with node-negative, estrogen receptor-positive breast cancer. J Clin Oncol 2006; 24: 3726–3734
   PubMed Web of Science ®Google Scholar
• Sparano J A, Paik S. Development of the 21-gene assay and its application in clinical practice and clinical trials. J Clin Oncol 2008; 26: 721–728
   PubMed Web of Science ®Google Scholar
• Wulfkuhle J D, Speer R, Pierobon M, et al. Multiplexed cell signaling analysis of human breast cancer applications for personalized therapy. J Proteome Res 2008; 7: 1508–1517
   PubMed Web of Science ®Google Scholar
• Carey L A, Perou C M, Livasy C A, et al. Race, breast cancer subtypes, and survival in the Carolina Breast Cancer Study. JAMA 2006; 295: 2492–2502
   PubMed Web of Science ®Google Scholar
• Ring B Z, Seitz R S, Beck R, et al. Novel prognostic immunohistochemical biomarker panel for estrogen receptor-positive breast cancer. J Clin Oncol 2006; 24: 3039–3047
   PubMed Web of Science ®Google Scholar
• Sudakin V, Yen T J. Targeting mitosis for anti-cancer therapy. BioDrugs 2007; 21: 225–233
   PubMed Web of Science ®Google Scholar
• Kossakowska A E, Huchcroft S A, Urbanski S J, Edwards D R. Comparative analysis of the expression patterns of metalloproteinases and their inhibitors in breast neoplasia, sporadic colorectal neoplasia, pulmonary carcinomas and malignant non-Hodgkin's lymphomas in humans. Br J Cancer 1996; 73: 1401–1408
   PubMed Web of Science ®Google Scholar
• Monteagudo C, Merino M J, San-Juan J, Liotta L A, Stetler-Stevenson W G. Immunohistochemical distribution of type IV collagenase in normal, benign, and malignant breast tissue. Am J Pathol 1990; 136: 585–592
   PubMed Web of Science ®Google Scholar
• Bramhall S R, Rosemurgy A, Brown P D, Bowry C, Buckels J A. Marimastat as first-line therapy for patients with unresectable pancreatic cancer: a randomized trial. J Clin Oncol 2001; 19: 3447–3455
   PubMed Web of Science ®Google Scholar
• Hidalgo M, Eckhardt S G. Development of matrix metalloproteinase inhibitors in cancer therapy. J Natl Cancer Inst 2001; 93: 178–193
   PubMed Web of Science ®Google Scholar
• Lakhani S R. The pathology of familial breast cancer: Morphological aspects. Breast Cancer Res 1999; 1: 31–35
   PubMedGoogle Scholar
• Lakhani S R, Reis-Filho J S, Fulford L, et al. Prediction of BRCA1 status in patients with breast cancer using estrogen receptor and basal phenotype. Clin Cancer Res 2005; 11: 5175–5180
   PubMed Web of Science ®Google Scholar